Literature DB >> 34250401

Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3 G623R Solvent-Front Mutation.

Dorothea Hanf1,2,3, Christoph Heining1,2,3, Karin Laaber4,5, Heiner Nebelung6, Sebastian Uhrig7,8,9, Barbara Hutter7,8,9, Arne Jahn1,2,3,10,11,12, Daniela Richter1,2,3, Daniela Aust13, Friederike Herbst4, Stefan Fröhling9,14, Hanno Glimm1,2,3,4, Gunnar Folprecht12,15.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34250401      PMCID: PMC8232550          DOI: 10.1200/PO.20.00278

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


× No keyword cloud information.
  21 in total

1.  Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.

Authors:  Miho J Fuse; Koutaroh Okada; Tomoko Oh-Hara; Hayato Ogura; Naoya Fujita; Ryohei Katayama
Journal:  Mol Cancer Ther       Date:  2017-07-27       Impact factor: 6.261

2.  Precision oncology based on omics data: The NCT Heidelberg experience.

Authors:  Peter Horak; Barbara Klink; Christoph Heining; Stefan Gröschel; Barbara Hutter; Martina Fröhlich; Sebastian Uhrig; Daniel Hübschmann; Matthias Schlesner; Roland Eils; Daniela Richter; Katrin Pfütze; Christina Geörg; Bettina Meißburger; Stephan Wolf; Angela Schulz; Roland Penzel; Esther Herpel; Martina Kirchner; Amelie Lier; Volker Endris; Stephan Singer; Peter Schirmacher; Wilko Weichert; Albrecht Stenzinger; Richard F Schlenk; Evelin Schröck; Benedikt Brors; Christof von Kalle; Hanno Glimm; Stefan Fröhling
Journal:  Int J Cancer       Date:  2017-06-21       Impact factor: 7.396

3.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

Authors:  Alexander Drilon; Ramamoorthy Nagasubramanian; James F Blake; Nora Ku; Brian B Tuch; Kevin Ebata; Steve Smith; Veronique Lauriault; Gabrielle R Kolakowski; Barbara J Brandhuber; Paul D Larsen; Karyn S Bouhana; Shannon L Winski; Robyn Hamor; Wen-I Wu; Andrew Parker; Tony H Morales; Francis X Sullivan; Walter E DeWolf; Lance A Wollenberg; Paul R Gordon; Dorothea N Douglas-Lindsay; Maurizio Scaltriti; Ryma Benayed; Sandeep Raj; Bethany Hanusch; Alison M Schram; Philip Jonsson; Michael F Berger; Jaclyn F Hechtman; Barry S Taylor; Steve Andrews; S Michael Rothenberg; David M Hyman
Journal:  Cancer Discov       Date:  2017-06-03       Impact factor: 39.397

4.  Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Authors:  Elena Ardini; Maria Menichincheri; Patrizia Banfi; Roberta Bosotti; Cristina De Ponti; Romana Pulci; Dario Ballinari; Marina Ciomei; Gemma Texido; Anna Degrassi; Nilla Avanzi; Nadia Amboldi; Maria Beatrice Saccardo; Daniele Casero; Paolo Orsini; Tiziano Bandiera; Luca Mologni; David Anderson; Ge Wei; Jason Harris; Jean-Michel Vernier; Gang Li; Eduard Felder; Daniele Donati; Antonella Isacchi; Enrico Pesenti; Paola Magnaghi; Arturo Galvani
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

5.  Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Authors:  Mark M Awad; Ryohei Katayama; Michele McTigue; Wei Liu; Ya-Li Deng; Alexei Brooun; Luc Friboulet; Donghui Huang; Matthew D Falk; Sergei Timofeevski; Keith D Wilner; Elizabeth L Lockerman; Tahsin M Khan; Sidra Mahmood; Justin F Gainor; Subba R Digumarthy; James R Stone; Mari Mino-Kenudson; James G Christensen; A John Iafrate; Jeffrey A Engelman; Alice T Shaw
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

6.  Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.

Authors:  Curtis R Chong; Magda Bahcall; Marzia Capelletti; Takayuki Kosaka; Dalia Ercan; Taebo Sim; Lynette M Sholl; Mizuki Nishino; Bruce E Johnson; Nathanael S Gray; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2016-07-01       Impact factor: 12.531

7.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

Authors:  Mariangela Russo; Sandra Misale; Ge Wei; Giulia Siravegna; Giovanni Crisafulli; Luca Lazzari; Giorgio Corti; Giuseppe Rospo; Luca Novara; Benedetta Mussolin; Alice Bartolini; Nicholas Cam; Roopal Patel; Shunqi Yan; Robert Shoemaker; Robert Wild; Federica Di Nicolantonio; Andrea Sartore Bianchi; Gang Li; Salvatore Siena; Alberto Bardelli
Journal:  Cancer Discov       Date:  2015-11-06       Impact factor: 39.397

8.  Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.

Authors:  Bruce W Konicek; Andrew R Capen; Kelly M Credille; Philip J Ebert; Beverly L Falcon; Gary L Heady; Bharvin K R Patel; Victoria L Peek; Jennifer R Stephens; Julie A Stewart; Stephanie L Stout; David E Timm; Suzane L Um; Melinda D Willard; Isabella H Wulur; Yi Zeng; Yong Wang; Richard A Walgren; Sau-Chi Betty Yan
Journal:  Oncotarget       Date:  2018-02-13

9.  The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

Authors:  Ryohei Katayama; Bo Gong; Noriko Togashi; Masaya Miyamoto; Masaki Kiga; Shiho Iwasaki; Yasuki Kamai; Yuichi Tominaga; Yasuyuki Takeda; Yoshiko Kagoshima; Yuki Shimizu; Yosuke Seto; Tomoko Oh-Hara; Sumie Koike; Naoki Nakao; Hiroyuki Hanzawa; Kengo Watanabe; Satoshi Yoda; Noriko Yanagitani; Aaron N Hata; Alice T Shaw; Makoto Nishio; Naoya Fujita; Takeshi Isoyama
Journal:  Nat Commun       Date:  2019-08-09       Impact factor: 14.919

10.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors:  A Drilon; G Li; S Dogan; M Gounder; R Shen; M Arcila; L Wang; D M Hyman; J Hechtman; G Wei; N R Cam; J Christiansen; D Luo; E C Maneval; T Bauer; M Patel; S V Liu; S H I Ou; A Farago; A Shaw; R F Shoemaker; J Lim; Z Hornby; P Multani; M Ladanyi; M Berger; N Katabi; R Ghossein; A L Ho
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.